Diane Reidy-Lagunes appointed chief of medical oncology at Duke

Neoadjuvant dostarlimab averts brutal surgery in 80% of patients with dMMR solid tumors

Three years ago, researchers from Memorial Sloan Kettering Cancer Center published stunning results: For the 5% of rectal cancer patients whose tumors are mismatch-repair deficient, neoadjuvant dostarlimab-gxly (Jemperli) has the makings of a silver bullet.

Duke receives $50M from anonymous donor for proton beam therapy

An anonymous donor made a $50 million gift to Duke University Health System toward the development of a proton beam therapy center. The donation is the largest philanthropic gift received by Duke University Health System.

January 17, 2025

Vol.51 No.02

Conversation with The Cancer Letter

Undergrad intern at MSK poses a profound question: What if Henrietta Lacks had a Black doctor?

Every summer since 2010, ten undergraduate students from diverse backgrounds get the opportunity to explore any curiosities they might have about careers in medicine at Memorial Sloan Kettering Cancer Center.

October 04, 2024

Vol.50 No.37

By Claire Marie Porter

In Brief

Dana-Farber, Fred Hutch, MSK, Hopkins form Cancer AI Alliance

Four NCI-designated cancer centers—Dana-Farber Cancer Institute, Fred Hutch Cancer Center, Memorial Sloan Kettering Cancer Center, and The Sidney Kimmel Comprehensive Cancer Center and Whiting School of Engineering at Johns Hopkins—have joined together and secured funding from AWS, Deloitte, Microsoft, and NVIDIA, to create the Cancer AI Alliance.

October 04, 2024

Vol.50 No.37

Clinical

Factors outside CAR T-cell therapy are associated with increased risk of secondary cancers after the treatment, meta-analysis shows
Subgroup analysis suggests risk of secondary cancers after CAR T-cell therapy is similar to risk after other therapies

A meta-analysis of 25 studies—totaling over 5,000 participants—focused on a question that has been troubling patients, physicians, and regulators: Does treatment with CAR T-cell therapy contribute to the development of secondary cancers?

September 13, 2024

Vol.50 No.34

By McKenzie Prillaman

In Brief

Vittoria Bocchi, Julia Brunner, Melissa Yao, Tzippora Chwat-Edelstein named 2024 Kravis WiSE fellows

From left to right: Vittoria Bocchi, Melissa Yao, Julia Brunner, Tzippora Chwat-EdelsteinVittoria Bocchi, Julia Brunner, Melissa Yao, and Tzippora Chwat-Edelstein, four Sloan Kettering Institute researchers, were named 2024 Marie-Josée Kravis Women in Science Endeavor, or Kravis WiSE, fellowship grant recipients.

March 08, 2024

Vol.50 No.10

Diane Reidy-Lagunes appointed chief of medical oncology at Duke

YOU MAY BE INTERESTED IN

Neoadjuvant dostarlimab averts brutal surgery in 80% of patients with dMMR solid tumors

Duke receives $50M from anonymous donor for proton beam therapy

Undergrad intern at MSK poses a profound question: What if Henrietta Lacks had a Black doctor?

Dana-Farber, Fred Hutch, MSK, Hopkins form Cancer AI Alliance

Factors outside CAR T-cell therapy are associated with increased risk of secondary cancers after the treatment, meta-analysis shows
Subgroup analysis suggests risk of secondary cancers after CAR T-cell therapy is similar to risk after other therapies

Vittoria Bocchi, Julia Brunner, Melissa Yao, Tzippora Chwat-Edelstein named 2024 Kravis WiSE fellows

Renew today!

Subscriber content

Never miss an issue!

Login

Diane Reidy-Lagunes appointed chief of medical oncology at Duke

YOU MAY BE INTERESTED IN

Neoadjuvant dostarlimab averts brutal surgery in 80% of patients with dMMR solid tumors

Duke receives $50M from anonymous donor for proton beam therapy

Undergrad intern at MSK poses a profound question: What if Henrietta Lacks had a Black doctor?

Dana-Farber, Fred Hutch, MSK, Hopkins form Cancer AI Alliance

Factors outside CAR T-cell therapy are associated with increased risk of secondary cancers after the treatment, meta-analysis showsSubgroup analysis suggests risk of secondary cancers after CAR T-cell therapy is similar to risk after other therapies

Vittoria Bocchi, Julia Brunner, Melissa Yao, Tzippora Chwat-Edelstein named 2024 Kravis WiSE fellows

Never miss an issue!

Login

Factors outside CAR T-cell therapy are associated with increased risk of secondary cancers after the treatment, meta-analysis shows
Subgroup analysis suggests risk of secondary cancers after CAR T-cell therapy is similar to risk after other therapies